Table 1. Baseline clinicopathological characteristics (n=613).
| Characteristic | No. (%) |
|---|---|
| Age (yr)* | 50.2 ± 10.8 |
| Extent of DCIS (cm)* | 3.2 ± 2.3 |
| Operation method | |
| Mastectomy | 242 (39.5) |
| Breast-conserving surgery | 371 (60.5) |
| Axillary staging method | |
| Axillary node dissection | 12 (1.9) |
| Sentinel node biopsy | 288 (47.0) |
| Not done | 313 (51.1) |
| Histologic subtype | |
| DCIS | 477 (77.8) |
| Microinvasive carcinoma | 136 (22.2) |
| Nuclear grade | |
| 1 | 53 (8.6) |
| 2 | 278 (45.4) |
| 3 | 282 (46.0) |
| Necrosis | |
| Absent | 218 (35.6) |
| Present | 395 (64.4) |
| Comedo type | |
| Absent | 426 (69.5) |
| Present | 187 (30.5) |
| ER | |
| Negative | 157 (25.6) |
| Positive | 456 (74.4) |
| PR | |
| Negative | 216 (35.2) |
| Positive | 397 (64.8) |
| p53 overexpression | |
| Negative | 486 (79.3) |
| Positive | 127 (20.7) |
| Ki-67 proliferation index (%) | |
| < 20 | 477 (77.8) |
| ≥ 20 | 136 (22.2) |
| Subtypes | |
| Luminal A | 354 (57.7) |
| Luminal B | 107 (17.5) |
| HER2+ | 106 (17.3) |
| Triple-negative | 46 (7.5) |
| Radiation therapy | |
| Not received | 246 (40.1) |
| Received | 367 (59.9) |
| Hormonal therapy | |
| Not received | 358 (58.4) |
| Received | 255 (41.6) |
DCIS=ductal carcinoma in situ; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
*Mean±SD.